CeNeS Pharmaceuticals licensed its preclinical recombinant GGF2 protein for treating multiple sclerosis to Acorda Therapeutics. Acorda also obtained a licence to NRG2, an earlier stage product with potential applications in MS, spinal cord injury and Parkinson’s. The deal could be worth up to US$13 M.